Latest Innovation News

Reckon Limited has reported a robust first half of 2025, marked by significant revenue and profit growth fueled by organic expansion and the acquisition of Cashflow Manager. The company’s cloud-based Reckon One product and US-focused Legal Group continue to drive momentum.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Austal Limited has finalized a Strategic Shipbuilding Agreement with the Commonwealth of Australia, positioning its subsidiary as the nation’s key Tier 2 naval shipbuilder. This long-term pact sets the stage for significant defence vessel construction in Western Australia.

Universal Biosensors reported a 44% increase in net loss to A$10.45 million for H1 2025, alongside an 11% revenue decline, raising serious going concern doubts. The company is pursuing an A$8.5 million senior secured loan and equity raise to sustain operations.

WT Financial Group has reported a strong 21% increase in underlying net profit before tax for FY2025, driven by robust revenue growth and improved operational efficiency. The company also announced a new joint venture aimed at fueling future expansion.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

HeraMED Limited has raised $1.98 million through a discounted share placement to fund its digital maternity care platform's commercial growth across the US, Australia, and Europe.

Element 25 Limited is advancing its Butcherbird Manganese Mine expansion in Western Australia alongside a new US-based refinery, backed by strong financing and partnerships with major automakers for EV battery-grade manganese supply.

Papyrus Australia Ltd has announced a $262,000 capital raise through a share placement and unlisted options, aiming to strengthen its working capital and research efforts.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.

Activeport Group Ltd has announced a fully underwritten rights issue to raise up to $2.5 million, offering shareholders discounted shares and free options to accelerate growth initiatives.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.